3 Formulations and API Major, Surface Treatment Chemical and Fortune Brand Stocks With a Strong Future Roadmap: Aurobindo Pharma, Grauer & Weil (India) and AWL Agri Business
- October 16, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Aurobindo Pharma Rs 1,677.90, P/E 25.46. Grauer & Weil Rs 79.04, P/E 22.12. AWL Agri Rs 190.54, P/E 20.49. Closing prices of 14 Oct 2026.
Quick Answer
Formulations and API major, surface treatment chemical and Fortune brand stocks with the clearest long-term roadmaps today include Aurobindo Pharma in generic formulations and active ingredients sold in the US, Europe and emerging markets, Grauer & Weil in surface treatment chemicals and related industrial products and AWL Agri in edible oils, packaged foods and staples sold under the Fortune brand. FY26 revenue growth was 5.6% at Aurobindo Pharma, 5.1% at Grauer & Weil and 17.6% at AWL Agri. P/E stands at 25.46 for Aurobindo Pharma (industry 37.59), 22.12 for Grauer & Weil (industry 36.60) and 20.49 for AWL Agri (industry 34.85). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.
Formulations and API major, surface treatment chemical and Fortune brand stocks give investors exposure to medicines, industrial chemicals and kitchen staples sold at home and abroad. Volumes, export demand and margins decide how much of that demand turns into profit.
Readers comparing formulations and API major, surface treatment chemical and Fortune brand stocks should weigh growth, margins, cash flow and valuation together instead of leaning on any single number.
This list covers three formulations and API major, surface treatment chemical and Fortune brand stocks: Aurobindo Pharma for generic formulations and active ingredients sold in the US, Europe and emerging markets, Grauer & Weil (India) for surface treatment chemicals and related industrial products and AWL Agri Business for edible oils, packaged foods and staples sold under the Fortune brand. Every figure comes from the latest reported financials and the 14 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Formulations and Api Major, Surface Treatment Chemical and Fortune Brand Stocks?
Formulations and API major, surface treatment chemical and Fortune brand stocks are shares of companies that make health products, chemicals or run restaurants. Results depend on volumes, store additions and margins, so margins and cash flow separate the stronger names.
Formulations and Api Major, Surface Treatment Chemical and Fortune Brand Stocks at a Glance
The table compares size, valuation, return on equity and debt for the three formulations and API major, surface treatment chemical and Fortune brand stocks as of the 14 Oct 2026 close.
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE | Debt to Equity |
|---|---|---|---|---|---|---|
| Aurobindo Pharma | 1,677.90 | 94,477 | 25.46 | 37.59 | 9.25% | 0.21 |
| Grauer & Weil (India) | 79.04 | 3,540 | 22.12 | 36.60 | 15.16% | 0.01 |
| AWL Agri Business | 190.54 | 23,732 | 20.49 | 34.85 | 9.98% | 0.11 |
Among healthcare, chemicals and consumer stocks, all three trade at a discount to their industry P/E multiples.
Valuation matters here because formulations and API major, surface treatment chemical and Fortune brand stocks can look attractive on growth and still look expensive on earnings.
Why Do Formulations and Api Major, Surface Treatment Chemical and Fortune Brand Stocks Have a Strong Roadmap in India?
Formulations and API major, surface treatment chemical and Fortune brand stocks have a strong roadmap in India because generic drug demand overseas, manufacturing output and branded staples keep adding volumes for these firms. Three drivers stand out.
- Generic demand: Overseas markets buy affordable formulations and ingredients.
- Manufacturing output: Factories use surface treatment chemicals.
- Branded staples: Households choose packaged oils and foods.
Aurobindo Pharma: Generic Formulations and Ingredients Build the Next Leg
Aurobindo Pharma’s roadmap rests on generic formulations and active ingredients sold in the US, Europe and emerging markets, with a wide product basket supporting export revenue.
Revenue grew from Rs 23,775.84 crore in FY22 to Rs 34,145.17 crore in FY26, a 43.6% rise, and FY26 revenue was 5.6% higher than FY25. FY26 net profit rose 0.6% to Rs 3,502.97 crore. Over four years, net profit rose from Rs 2,647.11 crore in FY22 to Rs 3,502.97 crore. In Q1 FY27, revenue grew 18.1% to Rs 9,414.58 crore, and net profit rose 25.2% to Rs 1,032.03 crore. Operating margin was 21.61% in FY26 and 23.10% in Q1 FY27 against 21.95% a year earlier.
Debt to equity is 0.21 and return on equity is 9.25%. FY26 operating cash flow was Rs 5,526.37 crore against capital expenditure of Rs 3,104.67 crore. Aurobindo Pharma paid a dividend of Rs 4 per share for FY26, a yield of 0.25%. At a P/E of 25.46 against an industry P/E of 37.59, the stock trades below its industry multiple.
What to watch: Q1 FY27 operating margin was 23.10% against 21.61% for FY26, so margin stability is the figure to follow as volumes grow.
Grauer & Weil (India): Surface Treatment Chemicals Drive the Pipeline
Grauer & Weil’s roadmap rests on surface treatment chemicals and related industrial products, with several business lines supporting earnings.
Revenue grew from Rs 782.11 crore in FY22 to Rs 1,239.78 crore in FY26, a 58.5% rise, and FY26 revenue was 5.1% higher than FY25. FY26 net profit rose 4.3% to Rs 164.03 crore. Over four years, net profit rose from Rs 78.77 crore in FY22 to Rs 164.03 crore. In Q1 FY27, revenue grew 17.0% to Rs 311.11 crore. Operating margin was 18.87% in FY26.
Debt to equity is 0.01 and return on equity is 15.16%. FY26 operating cash flow was Rs 151.86 crore against capital expenditure of Rs 53.65 crore. Grauer & Weil paid a dividend of Rs 1 per share for FY26, a yield of 1.28%. At a P/E of 22.12 against an industry P/E of 36.60, the stock trades below its industry multiple.
What to watch: The P/E of 22.12 against an industry P/E of 36.60 leaves valuation less stretched, so the next quarters’ growth is the figure to follow.
AWL Agri Business: Edible Oils and Staples Build the Next Leg
AWL Agri’s roadmap rests on edible oils, packaged foods and staples sold under the Fortune brand, with a wide distribution network supporting volumes.
Revenue grew from Rs 54,327.16 crore in FY22 to Rs 75,148.47 crore in FY26, a 38.3% rise, and FY26 revenue was 17.6% higher than FY25. FY26 net profit was Rs 990.44 crore. In Q1 FY27, revenue grew 16.5% to Rs 20,116.91 crore, and net profit rose 47.7% to Rs 351.39 crore. Operating margin was 3.38% in FY26 and 3.90% in Q1 FY27 against 3.39% a year earlier.
Debt to equity is 0.11 and return on equity is 9.98%. FY26 operating cash flow was Rs 3,928.34 crore against capital expenditure of Rs 833.37 crore. AWL Agri paid a dividend of Rs 1 per share for FY26, a yield of 0.55%. At a P/E of 20.49 against an industry P/E of 34.85, the stock trades below its industry multiple.
What to watch: Net profit margin is only 1.3%, so small cost changes move earnings.
Best Formulations and Api Major, Surface Treatment Chemical and Fortune Brand Stocks in India: Aurobindo Pharma vs Grauer & Weil vs AWL Agri on Key Financials
Among the best formulations and API major, surface treatment chemical and Fortune brand stocks in India, Aurobindo Pharma leads on FY26 operating margin and Q1 FY27 revenue growth; Grauer & Weil leads on return on equity and the lowest debt to equity; AWL Agri leads on FY26 revenue growth and the lowest P/E. The table puts the numbers side by side.
| Metric | Aurobindo Pharma | Grauer & Weil | AWL Agri |
|---|---|---|---|
| FY26 revenue (Rs Cr) | 34,145.17 | 1,239.78 | 75,148.47 |
| FY26 revenue growth | 5.6% | 5.1% | 17.6% |
| FY26 net profit (Rs Cr) | 3,502.97 | 164.03 | 990.44 |
| FY26 operating profit margin | 21.61% | 18.87% | 3.38% |
| Q1 FY27 revenue growth (YoY) | 18.1% | 17.0% | 16.5% |
| Return on equity | 9.25% | 15.16% | 9.98% |
| P/E ratio | 25.46 | 22.12 | 20.49 |
| Debt to equity | 0.21 | 0.01 | 0.11 |
| Dividend yield | 0.25% | 1.28% | 0.55% |
| FY26 operating cash flow (Rs Cr) | 5,526.37 | 151.86 | 3,928.34 |
Healthcare, chemicals and food earnings follow volumes, store additions and margins, so full-year numbers and quarterly trends together give a better view.
How to Evaluate Formulations and Api Major, Surface Treatment Chemical and Fortune Brand Stocks to Buy Before You Invest
A short checklist keeps the research consistent when you screen formulations and API major, surface treatment chemical and Fortune brand stocks and shortlist formulations and API major, surface treatment chemical and Fortune brand stocks to buy.
- Compare each stock’s P/E with its industry P/E, which differs by company here.
- Check revenue growth, operating margin and cash flow together.
- Check whether revenue growth is turning into profit growth, not only sales.
- Read operating cash flow against capital expenditure to see how growth is funded.
- Watch debt to equity and interest cover before sizing a position.
- Spread exposure across companies and business lines instead of one demand cycle.
Risks to Consider Before Investing in Formulations and Api Major, Surface Treatment Chemical and Fortune Brand Stocks
- Consumer demand: Spending patterns can shift sales between quarters.
- Input costs: Changes in raw material prices can affect margins.
- Quarterly trends: A single weak quarter can change near-term earnings, so track results every quarter.
Download the Univest iOS App or Univest Android App to track Aurobindo Pharma, Grauer & Weil and AWL Agri live.
Final Take: Which Stock Has the Strongest Roadmap?
These three healthcare, chemicals and consumer stocks cover generics, surface chemicals and edible oils. Aurobindo Pharma leads on FY26 operating margin and Q1 FY27 revenue growth; Grauer & Weil leads on return on equity and the lowest debt to equity; AWL Agri leads on FY26 revenue growth and the lowest P/E.
Across formulations and API major, surface treatment chemical and Fortune brand stocks, each roadmap still has to turn growth into steady profit, so independent research and position sizing matter. Investors should consult a SEBI-registered advisor before acting on any of the formulations and API major, surface treatment chemical and Fortune brand stocks to buy discussed here.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Formulations and Api Major, Surface Treatment Chemical and Fortune Brand Stocks
Which are the best formulations and API major, surface treatment chemical and Fortune brand stocks in India with a strong roadmap?
Ans. Aurobindo Pharma, Grauer & Weil (India) and AWL Agri Business stand out for their roadmaps in generics, surface chemicals and edible oils. FY26 revenue growth was 5.6% at Aurobindo Pharma, 5.1% at Grauer & Weil and 17.6% at AWL Agri, and return on equity ranges from 9.25% to 15.16%.
Is Aurobindo Pharma a good stock to buy now?
Ans. Aurobindo Pharma has a debt to equity ratio of 0.21, a return on equity of 9.25% and a P/E of 25.46 against an industry P/E of 37.59. Valuation, demand and input costs move results. This article is not investment advice, so consult a SEBI-registered advisor before deciding.
What is the P/E ratio of Aurobindo Pharma, Grauer & Weil and AWL Agri?
Ans. The P/E ratio is 25.46 for Aurobindo Pharma (industry 37.59), 22.12 for Grauer & Weil (industry 36.60) and 20.49 for AWL Agri (industry 34.85). All of them trade below the industry multiple.
Which of these formulations and API major, surface treatment chemical and Fortune brand stocks has the highest return on equity?
Ans. Grauer & Weil (India) has the highest return on equity at 15.16%, followed by AWL Agri Business at 9.98% and Aurobindo Pharma at 9.25%.
What are the risks of investing in formulations and API major, surface treatment chemical and Fortune brand stocks?
Ans. The main risks are consumer demand, input costs and quarterly trends. Spending patterns can shift sales between quarters.
How did Aurobindo Pharma, Grauer & Weil and AWL Agri perform in Q1 FY27?
Ans. Aurobindo Pharma reported revenue of Rs 9,414.58 crore, up 18.1% year on year, and net profit rose 25.2% to Rs 1,032.03 crore. Grauer & Weil (India) reported revenue of Rs 311.11 crore, up 17.0% year on year. AWL Agri Business reported revenue of Rs 20,116.91 crore, up 16.5% year on year, and net profit rose 47.7% to Rs 351.39 crore.
Do formulations and API major, surface treatment chemical and Fortune brand stocks pay dividends?
Ans. Yes, all three companies pay dividends. The dividend yield is 0.25% for Aurobindo Pharma, 1.28% for Grauer & Weil and 0.55% for AWL Agri, based on dividends declared for FY26.
How can I invest in formulations and API major, surface treatment chemical and Fortune brand stocks in India?
Ans. You can buy formulations and API major, surface treatment chemical and Fortune brand stocks through a demat and trading account on NSE or BSE after checking each company’s financials, margins and valuation. The Univest Screener lets you compare fundamentals before placing an order. Investments in securities are subject to market risk, so consider your risk profile first.
